Compare Illumina, Inc. (ILMN) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Mondaycom Ltd — how do they compare? Illumina, Inc. trades at $190.78 (market cap $29.12B), while Mondaycom Ltd trades at $84.85 (market cap $3.70B). The key difference: Illumina, Inc. is far larger — about 7.9× Mondaycom Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | MNDY | |
|---|---|---|
Market Cap | $29.12B | $3.70B |
Sector | Health | Technology |
52-Week High | $205.10 | $219.15 |
52-Week Low | $91.00 | $58.81 |
Enterprise Value | $30.48B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
MNDY trades at $84.52, down 4.63% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and robust gross margins of 88.74%. However, technical indicators are neutral with support at $83 and resistance at $89. Recent news highlights AI product growth but weaker Q3 revenue guidance caused a sell-off.
Outlook remains cautiously optimistic with a $113.38 consensus price target implying 34% upside. Key risks include slowing revenue growth guidance and competitive pressures. The 76% buy rating from analysts supports long-term potential, but near-term volatility may persist due to execution concerns and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
